{
    "info": {
        "nct_id": "NCT06069570",
        "official_title": "Phase 1 Trial Evaluating the Safety and Tolerability of Gamma Delta T-Cell Infusions in Combination with Low Dose Radiotherapy in Subjects with Locally Advanced or Metastatic Non-Small Cell Lung Cancer or Solid Tumors with Bone Metastases",
        "inclusion_criteria": "* Signed and dated informed consent form.\n* Male or female, > 18 years old.\n* Minimum body weight of 50 kilograms (kg).\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n* Histologically or cytologically confirmed locally advanced or metastatic NSCLC or locally advanced or metastatic solid tumor with bone metastasis\n* Progressed on SOC therapy including platinum-based chemotherapy and immune checkpoint inhibitors (NSCLC), and are not a candidate for further standard anti-neoplastic therapy and/or have exhibited intolerance to and/or declined clinically applicable salvage therapies, and/or have declined therapy.\n* Genomic screening, with tumors with known actionable molecular alterations, such as EGFR, ALK, ROS-1, BRAF, RET, MET, and KRAS etc., must have progressed on appropriate target-directed molecular therapy.\n* At least one measurable target lesion based on RECIST v1.1 confirmed by radiological imaging. Participants with isolated bone metastases are eligible for enrollment are not required to have measurable disease\n* All toxicity associated with previous treatments are recovered to CTCAE grade of ≤1, except for continuing alopecia.\n* Adequate hematopoietic, hepatic and renal function\n* Agree to adequate contraception for up to 120 days after the last dose of study drug.\n* Negative serum pregnancy test for women of childbearing potential\n* All primary and metastatic disease sites are amenable to LDRT\n* For solid tumors with bone metastases subjects (Part 2 Cohort B): receiving zoledronic acid for solid tumors with bone metastases\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Chemotherapy, investigational, and/or check-point inhibitor therapy within the 30 days prior to study Day 1.\n* Major surgery, except for vascular access placement, within the 30 days prior to study Day 1.\n* Active autoimmune disease requiring immunosuppressive therapy.\n* Infection requiring systemic treatment within 30 days prior to study Day 1.\n* History of peritoneal effusion (ascites), pericardial, or pleural effusions/nodules.\n* Uncontrolled hypertension, history of arrhythmia including atrial fibrillation, unstable angina, decompensated congestive heart failure, cardiac ejection fraction ≤ 50%, myocardial infarction, or marked baseline prolonged QT/QTc intervals.\n* Human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C detection.\n* Participation in the treatment portion of a clinical trial or completed a clinical trial within the 30 days prior to the first dose of KB-GDT-01.\n* Presence of any condition that may, in the opinion of the Investigator, render the patient inappropriate from participating in the study.\n* Breastfeeding or pregnant female, or patient is expecting to conceive or father children during the study.\n* Allergy or intolerance to any of the study product ingredients or excipients.\n* Live vaccines administered within 30 days prior to study Day 1.\n* Individuals lacking capacity to consent for themselves.\n* Superior vena cava obstruction\n* Prior radiation therapy to a selected LDRT treatment site </= 30 days prior to Day 1.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* All primary and metastatic disease sites are amenable to LDRT",
            "criterions": [
                {
                    "exact_snippets": "All primary and metastatic disease sites are amenable to LDRT",
                    "criterion": "primary and metastatic disease sites",
                    "requirements": [
                        {
                            "requirement_type": "amenability to LDRT",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Signed and dated informed consent form.",
            "criterions": [
                {
                    "exact_snippets": "Signed and dated informed consent form",
                    "criterion": "informed consent form",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "dated",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For solid tumors with bone metastases subjects (Part 2 Cohort B): receiving zoledronic acid for solid tumors with bone metastases",
            "criterions": [
                {
                    "exact_snippets": "solid tumors with bone metastases",
                    "criterion": "solid tumors with bone metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "receiving zoledronic acid",
                    "criterion": "zoledronic acid treatment",
                    "requirements": [
                        {
                            "requirement_type": "current treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically or cytologically confirmed locally advanced or metastatic NSCLC or locally advanced or metastatic solid tumor with bone metastasis",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically confirmed",
                    "criterion": "diagnosis confirmation method",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": [
                                "histological",
                                "cytological"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "locally advanced or metastatic NSCLC",
                    "criterion": "disease type and stage",
                    "requirements": [
                        {
                            "requirement_type": "disease",
                            "expected_value": "NSCLC"
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "locally advanced",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "locally advanced or metastatic solid tumor with bone metastasis",
                    "criterion": "disease type, stage, and metastasis site",
                    "requirements": [
                        {
                            "requirement_type": "disease",
                            "expected_value": "solid tumor"
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "locally advanced",
                                "metastatic"
                            ]
                        },
                        {
                            "requirement_type": "metastasis_site",
                            "expected_value": "bone"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Agree to adequate contraception for up to 120 days after the last dose of study drug.",
            "criterions": [
                {
                    "exact_snippets": "Agree to adequate contraception for up to 120 days after the last dose of study drug.",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "agreement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 120,
                                "unit": "days after the last dose of study drug"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* All toxicity associated with previous treatments are recovered to CTCAE grade of ≤1, except for continuing alopecia.",
            "criterions": [
                {
                    "exact_snippets": "All toxicity associated with previous treatments are recovered to CTCAE grade of ≤1",
                    "criterion": "toxicity from previous treatments",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "CTCAE grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except for continuing alopecia",
                    "criterion": "alopecia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Male or female, > 18 years old.",
            "criterions": [
                {
                    "exact_snippets": "Male or female",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "allowed_values",
                            "expected_value": [
                                "male",
                                "female"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "> 18 years old",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* At least one measurable target lesion based on RECIST v1.1 confirmed by radiological imaging. Participants with isolated bone metastases are eligible for enrollment are not required to have measurable disease",
            "criterions": [
                {
                    "exact_snippets": "At least one measurable target lesion based on RECIST v1.1 confirmed by radiological imaging",
                    "criterion": "measurable target lesion",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        },
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment_method",
                            "expected_value": "RECIST v1.1"
                        },
                        {
                            "requirement_type": "confirmation_method",
                            "expected_value": "radiological imaging"
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants with isolated bone metastases are eligible for enrollment are not required to have measurable disease",
                    "criterion": "isolated bone metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "measurable disease requirement",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Minimum body weight of 50 kilograms (kg).",
            "criterions": [
                {
                    "exact_snippets": "Minimum body weight of 50 kilograms (kg)",
                    "criterion": "body weight",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "kg"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate hematopoietic, hepatic and renal function",
            "criterions": [
                {
                    "exact_snippets": "Adequate hematopoietic ... function",
                    "criterion": "hematopoietic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... hepatic ... function",
                    "criterion": "hepatic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate ... renal function",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Genomic screening, with tumors with known actionable molecular alterations, such as EGFR, ALK, ROS-1, BRAF, RET, MET, and KRAS etc., must have progressed on appropriate target-directed molecular therapy.",
            "criterions": [
                {
                    "exact_snippets": "Genomic screening, with tumors with known actionable molecular alterations, such as EGFR, ALK, ROS-1, BRAF, RET, MET, and KRAS etc.",
                    "criterion": "tumor molecular alterations",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": [
                                "EGFR",
                                "ALK",
                                "ROS-1",
                                "BRAF",
                                "RET",
                                "MET",
                                "KRAS"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "must have progressed on appropriate target-directed molecular therapy",
                    "criterion": "progression on target-directed molecular therapy",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0-1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Negative serum pregnancy test for women of childbearing potential",
            "criterions": [
                {
                    "exact_snippets": "Negative serum pregnancy test",
                    "criterion": "serum pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "women of childbearing potential",
                    "criterion": "sex and reproductive status",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Participation in the treatment portion of a clinical trial or completed a clinical trial within the 30 days prior to the first dose of KB-GDT-01.",
            "criterions": [
                {
                    "exact_snippets": "Participation in the treatment portion of a clinical trial",
                    "criterion": "participation in treatment portion of a clinical trial",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "completed a clinical trial within the 30 days prior to the first dose of KB-GDT-01",
                    "criterion": "completion of a clinical trial",
                    "requirements": [
                        {
                            "requirement_type": "time since completion",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Breastfeeding or pregnant female, or patient is expecting to conceive or father children during the study.",
            "criterions": [
                {
                    "exact_snippets": "Breastfeeding or pregnant female",
                    "criterion": "female reproductive status",
                    "requirements": [
                        {
                            "requirement_type": "breastfeeding",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "pregnant",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "patient is expecting to conceive or father children during the study",
                    "criterion": "expectation to conceive or father children during the study",
                    "requirements": [
                        {
                            "requirement_type": "expectation to conceive or father children during the study",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Chemotherapy, investigational, and/or check-point inhibitor therapy within the 30 days prior to study Day 1.",
            "criterions": [
                {
                    "exact_snippets": "Chemotherapy ... within the 30 days prior to study Day 1.",
                    "criterion": "chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "administration_timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days before study Day 1"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "investigational ... within the 30 days prior to study Day 1.",
                    "criterion": "investigational therapy",
                    "requirements": [
                        {
                            "requirement_type": "administration_timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days before study Day 1"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "check-point inhibitor therapy within the 30 days prior to study Day 1.",
                    "criterion": "check-point inhibitor therapy",
                    "requirements": [
                        {
                            "requirement_type": "administration_timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days before study Day 1"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior radiation therapy to a selected LDRT treatment site </= 30 days prior to Day 1.",
            "criterions": [
                {
                    "exact_snippets": "Prior radiation therapy to a selected LDRT treatment site </= 30 days prior to Day 1.",
                    "criterion": "prior radiation therapy to a selected LDRT treatment site",
                    "requirements": [
                        {
                            "requirement_type": "time since prior radiation therapy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Infection requiring systemic treatment within 30 days prior to study Day 1.",
            "criterions": [
                {
                    "exact_snippets": "Infection requiring systemic treatment within 30 days prior to study Day 1.",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "systemic treatment"
                        },
                        {
                            "requirement_type": "time since treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days prior to study Day 1"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C detection.",
            "criterions": [
                {
                    "exact_snippets": "Human immunodeficiency virus (HIV) ... detection",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "detection",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Hepatitis B ... detection",
                    "criterion": "Hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "detection",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Hepatitis C detection",
                    "criterion": "Hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "detection",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Individuals lacking capacity to consent for themselves.",
            "criterions": [
                {
                    "exact_snippets": "Individuals lacking capacity to consent for themselves",
                    "criterion": "capacity to consent for themselves",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgery, except for vascular access placement, within the 30 days prior to study Day 1.",
            "criterions": [
                {
                    "exact_snippets": "Major surgery ... within the 30 days prior to study Day 1.",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days prior to study Day 1"
                            }
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "except for vascular access placement"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active autoimmune disease requiring immunosuppressive therapy.",
            "criterions": [
                {
                    "exact_snippets": "Active autoimmune disease requiring immunosuppressive therapy.",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "requiring immunosuppressive therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Presence of any condition that may, in the opinion of the Investigator, render the patient inappropriate from participating in the study.",
            "criterions": [
                {
                    "exact_snippets": "Presence of any condition that may, in the opinion of the Investigator, render the patient inappropriate from participating in the study.",
                    "criterion": "any condition deemed inappropriate by Investigator",
                    "requirements": [
                        {
                            "requirement_type": "Investigator opinion",
                            "expected_value": "condition renders patient inappropriate for study participation"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of peritoneal effusion (ascites), pericardial, or pleural effusions/nodules.",
            "criterions": [
                {
                    "exact_snippets": "History of peritoneal effusion (ascites)",
                    "criterion": "peritoneal effusion (ascites)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... pericardial ... effusions/nodules",
                    "criterion": "pericardial effusion",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... pleural effusions/nodules",
                    "criterion": "pleural effusion",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... pleural ... nodules",
                    "criterion": "pleural nodules",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Superior vena cava obstruction",
            "criterions": [
                {
                    "exact_snippets": "Superior vena cava obstruction",
                    "criterion": "superior vena cava obstruction",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Allergy or intolerance to any of the study product ingredients or excipients.",
            "criterions": [
                {
                    "exact_snippets": "Allergy or intolerance to any of the study product ingredients or excipients",
                    "criterion": "allergy to study product ingredients or excipients",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Allergy or intolerance to any of the study product ingredients or excipients",
                    "criterion": "intolerance to study product ingredients or excipients",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Live vaccines administered within 30 days prior to study Day 1.",
            "criterions": [
                {
                    "exact_snippets": "Live vaccines administered within 30 days prior to study Day 1.",
                    "criterion": "live vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "vaccine type",
                            "expected_value": "live"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled hypertension, history of arrhythmia including atrial fibrillation, unstable angina, decompensated congestive heart failure, cardiac ejection fraction ≤ 50%, myocardial infarction, or marked baseline prolonged QT/QTc intervals.",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled hypertension",
                    "criterion": "hypertension",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "history of arrhythmia including atrial fibrillation",
                    "criterion": "arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of arrhythmia including atrial fibrillation",
                    "criterion": "atrial fibrillation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable angina",
                    "criterion": "angina",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        }
                    ]
                },
                {
                    "exact_snippets": "decompensated congestive heart failure",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "compensation status",
                            "expected_value": "decompensated"
                        }
                    ]
                },
                {
                    "exact_snippets": "cardiac ejection fraction ≤ 50%",
                    "criterion": "cardiac ejection fraction",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 50,
                                "unit": "%"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "myocardial infarction",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "marked baseline prolonged QT/QTc intervals",
                    "criterion": "QT/QTc interval",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": "markedly prolonged at baseline"
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "* Progressed on SOC therapy including platinum-based chemotherapy and immune checkpoint inhibitors (NSCLC), and are not a candidate for further standard anti-neoplastic therapy and/or have exhibited intolerance to and/or declined clinically applicable salvage therapies, and/or have declined therapy.",
            "criterions": [
                {
                    "exact_snippets": "Progressed on SOC therapy including platinum-based chemotherapy and immune checkpoint inhibitors (NSCLC)",
                    "criterion": "progression on standard of care therapy",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "therapy_types",
                            "expected_value": [
                                "platinum-based chemotherapy",
                                "immune checkpoint inhibitors"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "not a candidate for further standard anti-neoplastic therapy",
                    "criterion": "eligibility for further standard anti-neoplastic therapy",
                    "requirements": [
                        {
                            "requirement_type": "candidate_status",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "have exhibited intolerance to ... clinically applicable salvage therapies",
                    "criterion": "tolerance to clinically applicable salvage therapies",
                    "requirements": [
                        {
                            "requirement_type": "tolerance",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "have declined clinically applicable salvage therapies",
                    "criterion": "acceptance of clinically applicable salvage therapies",
                    "requirements": [
                        {
                            "requirement_type": "acceptance",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "have declined therapy",
                    "criterion": "acceptance of therapy",
                    "requirements": [
                        {
                            "requirement_type": "acceptance",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}